Orexigen (OREX) Reports Q3 Loss of $0.33, Beats by 3c
More News related to OREX
- Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Four Senior Executives Join Orexigen(R) Therapeutics Management Team
- Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
- Orexigen (OREX) Reports Q3 Loss of $0.33, Beats by 3c
- Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
Orexigen Therapeutics, Inc. (NASDAQ: OREX) reports Q3 loss of $0.33, 3 cents better than the analyst estimate of ($0.36).
Related Categories
EarningsStocks Mentioned
-0.15Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
